Positive Data from a Phase 3 Clinical Study of AFREZZA

In general, treatment with AFREZZA (an inhalation Powder) was well-tolerated over 24 weeks by subjects with type 1 diabetes. The incidence of serious adverse events related to study drug was similar in the AFREZZA-Gen2 (2.3%), AFREZZA-MedTone (2.9%) and insulin aspart (1.8%) groups. (MannKind Corporation)